China Pharma Holdings (CPHI) Change in Accured Expenses (2010 - 2026)

China Pharma Holdings has reported Change in Accured Expenses for 17 years, with the latest figure at -$14258.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 81.91% year-over-year to -$14258.0; the trailing twelve-month figure through Mar 2026 stood at $530304.0 (down 24.28% YoY), and the FY2025 full-year result was $465753.0, up 8.01% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$14258.0, down from $432777.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $804339.0 in Q4 2022, with the low at -$450887.0 in Q1 2023.
• Historically, Change in Accured Expenses has averaged $107804.6 across 5 years, with a median of $25734.0 in 2023.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 579.2% — and 2023, when it jumped 940.44%.
• China Pharma Holdings' Change in Accured Expenses stood at $804339.0 in 2022, then sank by 47.67% to $420886.0 in 2023, then surged by 73.24% to $729131.0 in 2024, then plunged by 40.64% to $432777.0 in 2025, then sank by 103.29% to -$14258.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$14258.0 (Q1 2026), $432777.0 (Q4 2025), and -$68702.0 (Q3 2025), per Business Quant data.